The 90 patients in this trial were randomised into two groups – half received a single high-dose of stereotactic ablative radiotherapy or SABR, and the other had an equivalent dose of SABR but accumulated over four visits. When followed up one year later, there was a little difference in side effects and outcomes. The results indicate that SABR can be a safe and effective treatment for patients whose cancer has spread to their lungs, even when it’s delivered in a single session. In addition to clinical benefits, SABR has practical benefits for patients, such as fewer trips to a clinic, less time off work and lower treatment costs.

Results from this trial have been published in The International Journal of Radiation Oncology, Biology, Physics [Link] and The Journal of Clinical Oncology [Link]